Andere Sprachen Evoke Pharma, Inc.

Aktien

A3DL9U

US30049G2030

EVOK

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 30.04.2024			% 5 Tage	% 1. Jan.
0.45 ^USD	+2.27%		+1.47%	-57.16%

24.04.	Transcript : Evoke Pharma, Inc. - Special Call
21.03.	Evoke Pharma, Inc. kündigt Veränderungen im Vorstand zum 31. März 2024 an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications	17.04.
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer	21.03.
Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024	21.03.
Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024	21.03.
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results	14.03.
Evoke Pharma, Inc. Provides Earnings Guidance for 2024	14.03.
Evoke Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024	07.03.
Evoke Pharma Announces Closing of $7.5 Million Public Offering	14.02.
Evoke Pharma Prices Underwritten Public Offering	09.02.
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million	09.02.
Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray	30.11.
Evoke Pharma Says FDA Lists Latest US Patent for Gimoti in Orange Book	27.11.
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent	27.11.
Evoke Pharma : Failure to Satisfy Listing Rule - Form 8-K	22.11.
Evoke Pharma - United States Patent and Trademark Office Grants another Formulation Patent Covering GIMOTI	15.11.
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI	14.11.
Evoke Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.
Evoke Pharma Reports Third Quarter 2023 Financial Results	09.11.
Evoke Pharma and EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide	01.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Evoke Pharma, Inc.

Aktien

A3DL9U

US30049G2030

EVOK

Andere Sprachen

Filter